During Q3 2018 the big money sentiment increased to 1.57. That’s change of 0.35, from 2018Q2’s 1.22. 16 investors sold all, 38 reduced holdings as Aerie Pharmaceuticals, Inc. ratio increased. 58 grew stakes while 27 funds amassed stakes. Funds hold 43.94 million shares thus 9.94% more from 2018Q2’s 39.97 million shares.
Sectoral Asset Management reported 5.08% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Gw Henssler & stated it has 0.03% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 15,200 were accumulated by Dekabank Deutsche Girozentrale. 339 were accumulated by Tower Capital Limited Liability Corp (Trc). Pub Employees Retirement Association Of Colorado reported 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Utd Service Automobile Association accumulated 0% or 5,982 shs. The Pennsylvania-based Sei Invests Company has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Federated Pa reported 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Bank Of Montreal Can has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Alps Advsr holds 80,025 shs or 0.03% of its capital. United Advisers Lc stated it has 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Fmr Ltd Liability Corporation owns 975,003 shs. Macquarie Ltd invested in 0.01% or 80,674 shs. Balyasny Asset Management Limited Liability Company, Illinois-based fund reported 322,183 shs. Moreover, Benchmark Capital Advsrs has 1.55% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).
Aerie Pharmaceuticals, Inc. registered $20.70 million net activity with 1 insider buy and 9 selling transactions since July 2, 2018. On Thursday, September 13 Shares for $2.08 million were sold by RUBINO RICHARD J. On Monday, August 27 MITRO THOMAS A sold $11.45 million worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 190,000 shs. On Friday, November 16 the insider Cagle Gerald D. bought $83,493.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage
In total 2 analysts cover Aerie Pharmaceuticals (NASDAQ:AERI). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:AERI)’s analyst reports since September 11, 2018 according to StockzIntelligence Inc. On Tuesday, September 11 the firm has “Buy” rating given by Stifel Nicolaus. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.
13/11/2018 Broker: Oppenheimer Rating: Outperform New Target: $64 Initiates Coverage On
11/09/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $80 New Target: $87 Maintain
AERI reached $38.12 during the last trading session after $0.89 change.Currently Aerie Pharmaceuticals, Inc. is downtrending after 30.47% change in last December 14, 2017. AERI has also 383,899 shares volume. AERI underperformed by 30.47% the S&P500.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is valued at $1.73 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.
For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news released recently go to: Nasdaq.com, Benzinga.com, Businesswire.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well – Nasdaq” released on August 09, 2018, “Daily Biotech Pulse: FDA Nod For Mallinckrodt’s Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results – Benzinga” on November 15, 2018, “Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director – Business Wire” with a publish date: September 24, 2018, “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” and the last “This May Be A Good Time To Pick Up Aerie Pharmaceuticals In 2018 – Seeking Alpha” with publication date: October 30, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.